Locations:
Search IconSearch
February 10, 2022/Cancer/Surgical Oncology

Bioimpedance Spectroscopy May Be Best Tool for Preventing Breast Cancer-Related Chronic Lymphedema

Low-strength electrical current identifies at-risk patients with greater accuracy than tape measurement

Cross section of human breast cross section. 3d illustration

Bioimpedance spectroscopy (BIS) coupled with early compression treatment appears to be more effective than tape measure-triggered compression for preventing lymphedema after breast cancer surgery. According to a recent international, multicenter study, BIS can identify patients who are likely to benefit from early compression intervention with greater precision than tape measurement (TM) alone. In addition, BIS is associated with a significant absolute reduction in chronic lymphedema in women with breast cancer.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“The primary end point of the trial was the rate of chronic lymphedema using complex decongestive physiotherapy as a surrogate,” explains Cleveland Clinic radiation oncologist Chirag Shah, MD, a co-author of the randomized study. “Our data showed that there was a statistically significant reduction in chronic lymphedema when we used BIS to conduct prospective surveillance. Historically, approximately 20% of patients developed chronic lymphedema based on their need for complex decongestive physiotherapy, but BIS reduced that rate to only 7.9%.”

Mitigating the side effects of breast cancer treatment

In explaining the rationale behind this research, he emphasizes that lymphedema is a major potential side effect of breast cancer treatment that can have a profound impact on patients’ quality of life.

“Unfortunately, lymphedema is relatively common in patients with breast cancer, particularly in those with more advanced disease who require lymph node dissection, radiation therapy, and/or chemotherapy,” says Dr. Shah, Director of Clinical Research in the Department of Radiation Oncology at Taussig Cancer Institute. “Because the condition is associated with significant morbidity and quality-of-life-altering complications, we feel it is worthy of continuing research.”

According to Dr. Shah, the major driver of lymphedema is the amount of local/regional therapy that a patient receives for their breast cancer.

“There are several driving factors that increase the risk of lymphedema more than the patient’s age or the type of breast cancer itself,” he explains. “For example, women who require axillary lymph node dissection compared to sentinel lymph node biopsy suffer from higher rates of lymphedema, as do patients who require regional lymph node radiation. In addition, some forms of chemotherapy — such as taxane-based chemotherapy — are associated with a higher incidence of lymphedema.”

Advertisement

Comparing BIS to tape measurement

The multicenter, international trial enrolled 1,200 patients with newly diagnosed breast cancer between June 24, 2014 and September 11, 2018. All patients had undergone surgery for their cancer. Study subjects were randomized 1:1 to prospective surveillance by BIS (n=482) or tape measurement (n=442) and screened for lymphedema development at regular intervals for three years after breast cancer surgery. The rate of progression to chronic breast cancer-related lymphedema, following an intervention for subclinical lymphedema using a compression garment, served as the primary end point.

Dr. Shah notes that this is the first randomized trial to compare BIS to tape measurement as a method of breast cancer surveillance. In addition, it appears to be the largest study of early treatment for breast cancer-related lymphedema. “I don’t think there has ever been a similar study close to this size,” he says.

Approximately 14% of study participants progressed to chronic lymphedema after intervention with a compression garment; however, only 8% of patients in the BIS arm developed this complication compared to 19.2% in the tape-measurement group. Interestingly, the patients monitored with BIS also required fewer interventions/triggers than those in the tape-measurement group (20% vs. 28%).

These findings amount to an absolute reduction of 11.3% in the propensity to progress to chronic lymphedema with the use of BIS surveillance coupled with early intervention with a compression garment.

Importance of breast cancer surveillance

“These results imply that breast cancer patients who are at risk of developing lymphedema should undergo prospective lymphedema surveillance with BIS coupled with the early use of a compression garment,” Dr. Shah says, adding that the trial has shown BIS to be a far superior breast cancer-related lymphedema diagnostic technique as compared to tape measurement.

Advertisement

Related Articles

Immune checkpoint inhibitor illustration
June 12, 2026/Cancer/News & Insight

Immunotherapy Appears to Reduce the Risk of Secondary Primary Cancers

Large-scale database also reveals potential for immunotherapy to protect against cancer

T53 mutation illustration
June 10, 2026/Cancer/News & Insight

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Woman consoling another
June 5, 2026/Cancer/Blood Cancers

Equal Access to Modern Therapy May Help Eliminate Survival Differences in Multiple Myeloma

Research underscores the importance of access to timely diagnosis and treatment in this patient population.

Multiple myeloma cells
June 4, 2026/Cancer/Blood Cancers

Machine Learning Model Outperforms Standard Risk Tools for Multiple Myeloma

A Cleveland Clinic model combining clinical staging, genomics and AI predicts survival with 18% greater accuracy — and could help match patients to more effective treatments.

Dr. Kamath & colleagues in the lab
June 2, 2026/Cancer/News & Insight

Tissue Tumor Mutation Burden Outperforms Blood-Based Testing for Predicting Immunotherapy Response

Study serves as ‘cautionary tale’ for physicians tempted to rely on liquid biopsy results alone

Patient with nebulizer
June 1, 2026/Cancer/Innovations

Adding Novel Inhaled Agent May Improve Lung Cancer Outcomes

Direct delivery of viral-based vector KB707 to the lungs may boost anti-tumor response and help overcome immune checkpoint inhibitor resistance

Acupuncture in wrist
May 29, 2026/Cancer/Patient Support

Can Acupuncture Really Help with Cancer Treatment Side Effects?

Evidence-based recommendations for managing pain, nausea and other treatment reactions

Head and neck cancer illustration
May 28, 2026/Cancer

What Is the Outlook for Treatment De-Intensification Strategies for Head & Neck Cancer?

Emerging data and practice changes reduce toxicity burden of treatment

Ad